News

New article in Pharmacological Research describing our first CSEPAM

by AS | 31 August 2025
Image New article in Pharmacological Research describing our first CSEPAM

Published in Pharmacological Research in September 2025 - the first CSEPAM and its binding to CSE and its effect on H2S production as well as calcification. Read the full article by clicking on

https://doi.org/10.1016/j.phrs.2025.107869

Latest publication linking pathologic calcification with osteoarthritis

by AS | 30 January 2023
Image Latest publication linking pathologic calcification with osteoarthritis

Dr Ilaria Bernabei and the SULFISCON founders published this review which details the mechanisms leading to pathological calcification in cartilage and its role in osteoarthritis in Nature Reviews Rheumatology.

DOI. 10.1038/s41584-022-00875-4

Research of CSE's role in cartilage calcification published

by AS | 8 September 2021
Image Research of CSE's role in cartilage calcification published

Dr Sonia Nasi published her findings on the role of CSE in pathologic cartilage and tendon calcification and how a CSE activator can prevent this. Her article appeared in the journal Antioxidants.

The article is open access https://www.mdpi.com/2076-3921/10/9/1433/pd

Innosuisse application

by AS | 22 July 2021
Image Innosuisse application

Innosuisse accepted SULFISCON's application to support the development of an allosteric modulator of CSE as a treatment of pathologic calcification disorders

SULFISCON selected for BIOPOLE STARTUP FUND

On the 5th July 2023, BIOPOLE announced that it has selected SULFISCON for its BIOPOLE STARTUP FUND award, worth 45k CHF in the first year. This will help SULFISCON develop its medicinal chemistry program and support its ongoing research